Statutory Updates to Branded Prescription Drug Fee Regulations

Document 2025-24153 is a Proposed Rule published by the Department of the Treasury in the Federal Register on January 2, 2026. This document proposes amendments to regulations regarding the annual fee imposed on covered entities engaged in the business of manufacturing or importing certain branded prescription drugs. In response to the replacement of the Coverage Gap Discount Program with the new Manufacturer Discount Program by the Inflation Reduction Act of 2022, the proposed regulations would make updates regarding the discounts, rebates, and other price concessions used to determine branded prescription drug sales under Medicare Part D and would update for prior statutory changes. These proposed regulations would affect persons engaged in the business of manufacturing or importing certain branded prescription drugs. View the original at https://www.federalregister.gov/documents/2026/01/02/2025-24153/statutory-updates-to-branded-prescription-drug-fee-regulations.

No. Document 2025-24153 is not classified as economically significant under Executive Order 12866. Economically significant rules require OIRA review and are estimated to have impacts of $100 million or more per year.